Skip to main content
Log in

Effectiveness of shielding materials against 177Lu gamma rays and the corresponding distance relationship

  • Short Communication
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The purpose of this study is to determine the dose reduction of different shielding materials at various distances from a 177Lu photon radiation source.

Methods

Two protective aprons with lead equivalent thicknesses of 0.25 mm and 0.35 mm and tungsten-containing rubber (TCR) were used as shielding materials. A vial containing 177Lu was sealed in a lead container so that a narrow beam went out through a 3 mm-diameter hole. The dose rate was measured at distances of 0, 10, 50, 100, and 200 cm from the source using a NaI scintillation survey meter to obtain the rate of dose reduction. TCR was tested with thicknesses ranging from 0.3 to 1.0 mm at 0.1 mm intervals and from 1.0 to 4.0 mm at 0.5 mm intervals.

Results

At distances of 0, 10, 50, 100, and 200 cm, the dose reduction for the lead equivalent thickness of 0.25 mm were 32.7%, 54.5%, 93.1%, 97.9%, and 99.6%, respectively; and for the lead equivalent thickness of 0.35 mm were 53.4%, 70.6%, 95.6%, 98.9%, and 99.6%, respectively. Without any shielding, the dose rate decreased by 34.4% at 10 cm and by 88.8% at 50 cm from the radiation source. The dose reduction for the TCR thickness of 3.5 mm was 89.8% at 0 cm and 93.3% at 10 cm. The TCR thickness of 0.4 mm provided a dose reduction comparable to or greater than that of the 0.25 mm lead equivalent, whereas the TCR thickness of 1.0 mm or greater provided a dose reduction comparable to that of the 0.35 mm lead equivalent.

Conclusions

Achieving a reduction of 95% or more requires the 0.25 mm lead equivalent for a distance of 100 cm, the 0.35 mm lead equivalent for 50 cm, the TCR thickness of 0.3 mm for 100 cm, or the TCR thickness of 0.9 mm for 50 cm. Without wearing a protective apron, a reduction of approximately 95% is observed at distances greater than 100 cm. These findings would be useful for medical staff engaging in related activities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Novartis. Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer. Novartis. Basel: Massachusetts Medical Society 2022. https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. Accessed 2023 Apr 11

  2. Hosono M, Ikebuchi H, Nakamura Y, Nakamura N, Yamada T, Yanagida S, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy. Ann Nucl Med. 2018;32:217–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kusakabe K, Yokoyama K, Ito K, Shibuya H, Kinuya S, Ito M, et al. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy. Ann Nucl Med. 2012;26:370–8.

    Article  CAS  PubMed  Google Scholar 

  4. World Health Organization. Cancer population fact sheet: World. World Health Organization 2022. https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-s Accessed 2023 Apr 18

  5. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58:1956–61.

    Article  CAS  PubMed  Google Scholar 

  6. Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Phys. 2012;102:271–91.

    Article  CAS  PubMed  Google Scholar 

  7. Taniguchi Y, Wakabayashi H, Yoneyama H, Chen Z, Morino K, Otosaki A, et al. Application of a tungsten apron for occupational radiation exposure in nursing care of children with neuroblastoma during 131I-meta-iodo-benzyl-guanidine therapy. Sci Rep. 2022;12:47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kijima K, Krisanachinda A, Pasawang P, Hanaoka K, Monzen H, Nishimura Y. Shielding efficiency of novel tungsten rubber against radionuclides of 99mTc, 131I, 18F and 68Ga. Radiat Phys Chem. 2020;172:108755.

    Article  CAS  Google Scholar 

  9. Monzen H, Kanno I, Fujimoto T, Hiraoka M. Estimation of the shielding ability of a tungsten functional paper for diagnostic x-rays and gamma rays. J Appl Clin Med Phys. 2017;18:325–9.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kijima K, Monzen H, Matsumoto K, Tamura M, Nishimura Y. The shielding ability of novel tungsten rubber against the electron beam for clinical use in radiation therapy. Anticancer Res. 2018;38:3919–27.

    Article  CAS  PubMed  Google Scholar 

  11. Murata T, Miwa K, Matsubayashi F, Wagatsuma K, Akimoto K, Fujibuchi T, et al. Optimal radiation shielding for beta and bremsstrahlung radiation emitted by 89Sr and 90Y: validation by empirical approach and Monte Carlo simulations. Ann Nucl Med. 2014;28:617–22.

    Article  CAS  PubMed  Google Scholar 

  12. Japan Radioisotope Association. Radioisotope pocket data book. 10th ed. Japan Radioisotope Association, editor. Tokyo: Japan Radioisotope Association; 2020

  13. Jones AK, Wagner LK. On the (f)utility of measuring the lead equivalence of protective garments. Med Phys. 2013;40:063902.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Demir M, Abuqbeitah M, Uslu-Beşli L, Yıldırım Ö, Yeyin N, Çavdar İ, et al. Evaluation of radiation safety in 177Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot. 2016;36:269–78.

    Article  CAS  PubMed  Google Scholar 

  15. Espinoza S, Müller M, Jenneboer H, Peulen L, Bradley T, Purschke M, et al. Characterization of micro- and nanoscale LuPO4:Pr3+, Nd3+ with strong UV-C emission to reduce X-ray doses in radiation therapy. Part Part Syst Charact. 2019;36:1900280.

    Article  CAS  Google Scholar 

  16. Monzen H, Tamura M, Kijima K, Otsuka M, Matsumoto K, Wakabayashi K, et al. Estimation of radiation shielding ability in electron therapy and brachytherapy with real time variable shape tungsten rubber. Phys Med. 2019;66:29–35.

    Article  PubMed  Google Scholar 

  17. Tajiri M, Sunaoka M, Fukumura A, Endo M. A new radiation shielding block material for radiation therapy. Med Phys. 2004;31:3022–3.

    Article  PubMed  Google Scholar 

  18. Yue K, Luo W, Dong X, Wang C, Wu G, Jiang M, et al. A new lead-free radiation shielding material for radiotherapy. Radiat Prot Dosimetry. 2009;133:256–60.

    Article  CAS  PubMed  Google Scholar 

  19. Jamal AbuAlRoos N, Azman MN, Baharul Amin NA, Zainon R. Tungsten-based material as promising new lead-free gamma radiation shielding material in nuclear medicine. Phys Med. 2020;78:48–57.

    Article  PubMed  Google Scholar 

  20. Crowe SB, Charles PH, Cassim N, Maxwell SK, Sylvander SR, Smith JG, et al. Predicting the required thickness of custom shielding materials in kilovoltage radiotherapy beams. Phys Med. 2021;81:94–101.

    Article  PubMed  Google Scholar 

  21. Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 2019;6:7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–13.

    Article  CAS  PubMed  Google Scholar 

  23. Inada M, Monzen H, Matsumoto K, Tamura M, Minami T, Nakamatsu K, et al. A novel radiation-shielding undergarment using tungsten functional paper for patients with permanent prostate brachytherapy. J Radiat Res. 2018;59:333–7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Mark R. Kurban from Edanz (https://www.jp.edanz.com/ac) edited a draft of this paper. This work was supported by JSPS KAKENHI Grant Number 21K07576. No potential conflicts of interest were disclosed.

Funding

This work was supported by JSPS KAKENHI Grant Number 21K07576.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katsuya Okuhata.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 19 KB)

Supplementary file2 (DOCX 28 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okuhata, K., Monzen, H., Nakamura, Y. et al. Effectiveness of shielding materials against 177Lu gamma rays and the corresponding distance relationship. Ann Nucl Med 37, 629–634 (2023). https://doi.org/10.1007/s12149-023-01860-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-023-01860-x

Keywords

Navigation